These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3450474)

  • 1. [Clinical significance of ascitic fluid FDP and fibrinolytic activity assay].
    Lu XG; Chen CS; Ye ZY
    Zhonghua Nei Ke Za Zhi; 1987 Sep; 26(9):530-2, 565. PubMed ID: 3450474
    [No Abstract]   [Full Text] [Related]  

  • 2. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
    Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
    Agarwal S; Joyner KA; Swaim MW
    Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relation between fibrin/fibrinogen degradation products in malignant fluids and the fibrinolytic activity of the peritoneum].
    Takahashi M; Yoshida K; Kano K; Machida T; Nakamura Y; Miura Y; Miura N; Kanno S
    Gan No Rinsho; 1986 Dec; 32(15):1945-9. PubMed ID: 3806965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Paternoster A; Pengo V; Marchesoni D
    Clin Exp Obstet Gynecol; 1981; 8(2):64-5. PubMed ID: 7199979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Identification of fibrinogen or fibrin degradation products in the ascitic fluid].
    Kolodie L; Detante J; Rachail M
    Nouv Presse Med; 1978 Feb; 7(8):665. PubMed ID: 417295
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fibrin degradation products (FDP) and fibrinolytic activity of blood in various acute and chronic diseases].
    Kotschy M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):425-30. PubMed ID: 63429
    [No Abstract]   [Full Text] [Related]  

  • 8. Fibrinolytic activity in coronary heart disease.
    Yao SK; Chen ZJ; Tao SQ
    Chin Med J (Engl); 1989 Sep; 102(9):660-3. PubMed ID: 2517077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
    Collatos C; Barton MH; Prasse KW; Moore JN
    J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic importance of ascitic fluid sugar in tubercular peritonitis.
    Purohit SD; Store SD
    J Assoc Physicians India; 1974 May; 22(5):389-94. PubMed ID: 4422554
    [No Abstract]   [Full Text] [Related]  

  • 11. [Behavior of some indices of fibrinolysis (fibrinogen, FDP, plasminogen) in mature diabetics].
    Di Cesare E; Quartarone M; Cucinotta D; Coppolino E; Squadrito G
    Minerva Med; 1979 May; 70(22):1597-9. PubMed ID: 450299
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
    Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
    Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fibrinolytic activity of the blood and synovial fluid in patients with rheumatoid arthritis].
    Erov NK
    Ter Arkh; 1986; 58(7):73-7. PubMed ID: 2945279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascitic fluid in tuberculosis and heart failure.
    Sen P
    J Med Soc N J; 1974 May; 71(5):375-7. PubMed ID: 4524260
    [No Abstract]   [Full Text] [Related]  

  • 15. Etiological diagnosis of ascites.
    Mehrotra MP; Saxena KK; Mathur DC
    Indian J Med Res; 1972 Jul; 60(7):1089-100. PubMed ID: 4661457
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Pengo V; Marchesoni D
    Eur J Gynaecol Oncol; 1981; 2(3):127-8. PubMed ID: 7347682
    [No Abstract]   [Full Text] [Related]  

  • 18. Gastric fibrinolysis.
    Nilsson IM; Bergentz SE; Hedner U; Kullenberg K
    Thromb Diath Haemorrh; 1975 Nov; 34(2):409-18. PubMed ID: 807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic evaluation of ascitic adenosine deaminase activity in tubercular peritonitis.
    Gupta VK; Mukherjee S; Dutta SK; Mukherjee P
    J Assoc Physicians India; 1992 Jun; 40(6):387-9. PubMed ID: 1452564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.